NEW DELHI, India, 02 May 2024 — Abbott, the global healthcare company, announced the launch of XIENCE Sierra™ Everolimus (drug) Eluting Coronary Stent System in India. XIENCE Sierra is one of the latest generation stents in the XIENCE™ family, now available to people suffering from blocked coronary arteries. For interventional cardiologists, it brings unparalleled safety to the most complex cases.
Abbott has developed several tools and devices that have improved the angioplasty procedure over the years. Percutaneous coronary intervention (PCI), also called coronary angioplasty, is a nonsurgical, minimally invasive procedure that improves blood flow to the heart. Physicians use PCI to open blood vessels to the heart that are narrowed or blocked by plaque1. Often, a small mesh tube called a stent is placed to keep the artery open.
XIENCE is one of the most-used drug-eluting stents in the world. XIENCE Sierra improves upon previous versions of XIENCE with an enhanced stent design, a new delivery system, and unique sizes to help doctors treat challenging cases. XIENCE Sierra has the same highly specialized coating that lowers the likelihood of the artery becoming re-blocked, found in other XIENCE stents. XIENCE stents collectively have an unparalleled safety record from more than 120+ clinical trials involving 120,000 patients. As per published data, the stent has proved efficacy in difficult to treat, narrowed lesions and patients with complex conditions.
"We’ve launched XIENCE Sierra in India so that physicians can smoothly deliver the stent even in challenging cases," said Tushar Sharma, General Manager for Abbott’s vascular business in India & South Asia. "The innovative design and improved deliverability mean physicians can access and unblock difficult-to-treat lesions with more flexibility and precision. With the incidence of coronary artery disease on the rise in India, it’s important for us to provide technologies that help doctors optimally implant stents, so patients have the best outcomes possible."
XIENCE Sierra’s features include greater expansion range. This is helpful when the heart vessel is of different sizes at both ends. Importantly the stent offers stability due to its high longitudinal strength2 that minimizes the risk of its deformation. It can be better pushed and tracked so that physicians have more confidence in outcomes and safety for their patients. It’s a reliable stent because it allows physicians to perform tough techniques with more ease such as maneuvering and crossing through complex calcified lesions. One of the unique offerings with XIENCE Sierra is that it’s easy to use which helps treat challenging anatomies in patients with complex conditions.
Cardiovascular diseases are the leading cause of mortality within the category of non-communicable diseases in India3. Indians are also known to have a high prevalence coronary artery disease (CAD) or blockages of the arteries at 21.4% for patients with diabetes and 11% for non-diabetics4. Since the first coronary angioplasty was performed in 1977 with a catheter and balloon, this technology and clinical knowledge has progressed into a lifesaving procedure in cardiovascular disease segment.
Tushar further adds, " In addition to offering next-generation stents, Abbott is helping physicians by providing technologies that enable them to implant stents most efficiently. We’ve launched AI enabled imaging tools and diagnostics to provide everything an interventional cardiologist needs to perform complex coronary interventions."
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. In India, Abbott was established in 1910, and is one of the country's oldest and most admired healthcare companies. With more than 12,000 employees in the country, Abbott is helping to meet the healthcare needs of consumers, patients, and doctors throughout urban and rural India.
Connect with us at www.abbott.com and www.abbott.in, and on Facebook and India Facebook, LinkedIn, Instagram, X and YouTube.
The information mentioned in this document is only suggestive/for patient education and shall not be considered as a substitute for doctor’s advice or recommendations from Abbott. Please consult your doctor for more information
Abbott Media:
Mandira Viegas: mandira.viegas@abbott.com
References:
1 Tests performed by and data on file at Abbott. XIENCE Sierra™ Stent
2https://www.nhlbi.nih.gov/health/heart-treatments-procedures
3 Data on file at Abbott. XIENCE Sierra stent was compared to Resolute Onyx Stent, Synergy Stent and Orsiro Stent.
4https://www.statista.com/topics/7456/cardiovascular-disease-in-india/#topicOverview
5https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994761/
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.
FOLLOW ABBOTT